Discovery and Characterization of the Potent and Highly Selective 1,7-Naphthyridine-Based Inhibitors BAY-091 and BAY-297 of the Kinase PIP4K2A.


Journal

Journal of medicinal chemistry
ISSN: 1520-4804
Titre abrégé: J Med Chem
Pays: United States
ID NLM: 9716531

Informations de publication

Date de publication:
11 11 2021
Historique:
pubmed: 27 10 2021
medline: 1 2 2022
entrez: 26 10 2021
Statut: ppublish

Résumé

PIP4K2A is an insufficiently studied type II lipid kinase that catalyzes the conversion of phosphatidylinositol-5-phosphate (PI5P) into phosphatidylinositol 4,5-bisphosphate (PI4,5P

Identifiants

pubmed: 34699202
doi: 10.1021/acs.jmedchem.1c01245
doi:

Substances chimiques

Enzyme Inhibitors 0
Naphthyridines 0
Reactive Oxygen Species 0
PIP4K2A protein, human EC 2.7.1.-
Phosphotransferases (Alcohol Group Acceptor) EC 2.7.1.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

15883-15911

Auteurs

Lars Wortmann (L)

Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany.

Nico Bräuer (N)

Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany.

Simon J Holton (SJ)

Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany.

Horst Irlbacher (H)

Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany.

Jörg Weiske (J)

Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany.

Christian Lechner (C)

Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany.

Robin Meier (R)

Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany.

Jakob Karén (J)

Pelago Bioscience AB, Banvaktsvägen 20, 171 48 Solna, Sweden.

Catrine Berthold Siöberg (CB)

Pelago Bioscience AB, Banvaktsvägen 20, 171 48 Solna, Sweden.

Vera Pütter (V)

Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany.

Clara D Christ (CD)

Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany.

Antonius Ter Laak (A)

Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany.

Philip Lienau (P)

Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany.

Ralf Lesche (R)

Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany.

Barbara Nicke (B)

Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany.

Shing-Hu Cheung (SH)

Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany.

Marcus Bauser (M)

Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany.

Andrea Haegebarth (A)

Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany.

Franz von Nussbaum (F)

Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany.

Dominik Mumberg (D)

Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany.

Clara Lemos (C)

Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH